According to a new study published on Oncogene, the compound thymoquinone (TQ) selectively kills prostate cancer cells in the late stages. Led by researchers at Kanazawa University, the study reported that prostate cancer cells with the SUCLA2 gene deletion can be used as therapeutic targets. Prostate cancer lacking SUCLA2 accounts for the majority of hormone therapy or metastatic resistance, so new treatment options for this disease will bring huge benefits…